Search Results - "Deudon, S."

CANOPY-1: A phase III, placebo-controlled study of pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) with/without canakinumab in untreated patients (pts) with stage IIIB/IIIC-IV NSCLC by Tan, D.S.W., Kim, T.M., Solomon, B.J., Tan, W.L., Yu, C.-J., Geater, S., De Castro, G., Greystoke, A., Felip, E., Johnson, B.E., Deudon, S., Louveau, A.-L., Passos, V.Q., Cho, B.C.

Get full text

Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): Results from the confirmatory phase 3 ASCEND-5 study by Scagliotti, G., Kim, T.M., Crinò, L., Liu, G., Gridelli, C., Novello, S., Kiura, K., Bearz, A., Gautschi, O., Felip, E., Nishio, M., Spigel, D.R., Mok, T.S.K., Urban, P., Deudon, S., Zheng, C., Shaw, A.T.

Get full text

Copper-catalyzed general CN and CO bond cross-coupling with arylboronic acid by Lam, Patrick Y.S, Vincent, Guillaume, Clark, Charles G, Deudon, Sophie, Jadhav, Prabhakar K

“…General catalytic Cu(OAc) 2/TEMPO in air or Cu(OAc) 2/O 2 systems for the CN and CO cross-coupling reactions with arylboronic acid have been discovered. N-…”
Get full text

444PD Patient-reported outcomes (PROs) in ASCEND-5: A randomized, phase 3 study of ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase rearranged (ALK+) NSCLC previously treated with CT and crizotinib (CRZ) by Mok, T.S.K., Scagliotti, G., Kim, T.M., Crino, L., Liu, G., Gridelli, C., Novello, S., Kiura, K., Bearz, A., Gautschi, O., Felip, E., Nishio, M., Spigel, D.R., Urban, P., Deudon, S., Zheng, C., Shaw, A.T.

Get full text

444PD Patient-reported outcomes (PROs) in ASCEND-5: A randomized, phase 3 study of ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase rearranged (ALK+) NSCLC previously treated with CT and crizotinib (CRZ) by Mok, T.S.K., Scagliotti, G., Kim, T.M., Crinò, L., Liu, G., Gridelli, C., Novello, S., Kiura, K., Bearz, A., Gautschi, O., Felip, E., Nishio, M., Spigel, D.R., Urban, P., Deudon, S., Zheng, C., Shaw, A.T.

Get full text

Abstract OT2-6-04: Dovitinib, a receptor tyrosine kinase inhibitor in combination with fulvestrant in postmenopausal endocrine resistant human epidermal growth factor receptor 2 negative (HER2-) / hormone receptor-positive (HR+) breast cancer: A phase II, randomized, double blind, placebo-controlled study by Andre, F, Neven, P, Musolino, A, Latini, L, Campone, M, Cortes, J, Barrios, C, Squires, M, Zhang, Y, Deudon, S, Gogov, S, Blackwell, K

“…Abstract Background: Overcoming endocrine resistance is a critical goal in the treatment of HR+ breast cancer. Emerging in vitro evidence suggests that…”
Get full text

Copper-Promoted C−N Bond Cross-Coupling with Hypervalent Aryl Siloxanes and Room-Temperature N-Arylation with Aryl Iodide by Lam, Patrick Y. S., Deudon, Sophie, Averill, Kristin M., Li, Renhua, He, Ming Y., DeShong, Philip, Clark, Charles G.

Get full text

α-Nitrogen activating effect in the room temperature copper-promoted N-arylation of heteroarylcarboxamides with phenyl siloxane or p-toluylboronic acid by Lam, Patrick Y.S, Deudon, Sophie, Hauptman, Elisabeth, Clark, Charles G

“…Heteroarylcarboxamides containing α-nitrogens undergo copper-promoted N-phenylation with hypervalent phenyl trimethylsiloxane at room temperature, in the…”
Get full text